Information Provided By:
Fly News Breaks for September 25, 2019
CHRS
Sep 25, 2019 | 14:39 EDT
After speaking with Coherus Biosciences' management, Mizuho analyst Salim Syed says that the company continues to guide to 20% 2019 exit pegfilgrastim volume market share and that the 20% number that management refers to is based on IMS data not Symphony data. Additionally, the analyst says that management noted several times that the nature of the data in any given month can be lumpy and that inventory is something of which investors should be mindful. Syed has a Buy rating and $43 price target on the shares.
News For CHRS From the Last 2 Days
There are no results for your query CHRS